Expand into Europe: unlocking the orphan drug market
The European orphan drug market is growing rapidly, offering U.S. biotech companies a significant opportunity for expansion. However, navigating the region’s complex regulatory, pricing, and reimbursement landscapes requires a strategic approach.
In this exclusive guide, we cover:
- Key regulatory pathways and market entry considerations for orphan drugs in Europe
- How to leverage early access programs and real-world data for market adoption
- The benefits of partnering with European specialists to streamline distribution and compliance
- Best practices for patient engagement, advocacy, and long-term market success
Download this guide to learn how to successfully commercialize your orphan drug in Europe, ensuring both patient impact and commercial viability.
About Sciensus
Sciensus is a leading European life sciences organisation with over 30 years of experience connecting patients with life-changing medications. We’re redefining patient-centric care, connecting patients with life-changing medicines while empowering pharmaceutical companies and healthcare professionals with the insights needed to improve people’s lives.
Read more on…
Blogs
Out-licensing vs partnering: Strategies for accessing Europe
Out-licensing, partnering or going it alone. What is the best strategy to access Europe? Many US biotech and pharma companies…
Thought Leadership
EU orphan drug roll out: navigating regulatory challenges
Blogs
Planning your EU orphan drug stock management with Sciensus
Launching an orphan drug across multiple European Union (EU) countries is a complex task that requires careful planning and execution.…